The ingredient E-OA-07 is a blend of seven ayurvedic ingredients, such as ashwagandha, shyonaka (oroxylum indicum), and shunthi (zingiber officinale).
The trial looked at the efficacy of E-OA-07 at 1,000mg in alleviating the symptoms of moderate-to-severe cases of knee osteoarthritis.
Using the E-OA-07 manufactured and sold by Enovate Biolife under the tradename Lanconone, the results of the trial were recently published in The Journal of Pain Research.
Forty-four participants aged 40 to 65 completed the randomised, double-blind, placebo-controlled study.
To qualify for the study, they needed to have a history of joint paint for at least three years, body mass index within the range of 25 to 29.9, and knee joint pain of at least 60, based on a 100-point pain visual-analogue scale score.
During the study, the treatment group had to take two capsules of E-OA-07, each 500mg, after breakfast.
To find out the effects of E-OA-07, the participants’ pain scores were then measured based on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and it was found that the treatment group had a lower pain score.
For instance, the mean pain score of the treatment group had dropped from 14.95 ± 1.72 to 8.14 ± 3.83.
As for the placebo group, the mean pain score did not show drastic change, hovering between 14.87 ± 1.87 and 14.30 ± 3.81.
The researchers noted that the effects of E-OA-07 became significant from the 4th week of the study.
In addition, by the end of the study period, there was a clinically relevant change of 45.55%, 45.91% and 38.19% for pain, stiffness and physical function respectively.
“Overall, results of the present study support the effectiveness and safety of E-OA-07 in individuals suffering from symptoms of knee osteoarthritis,” the researchers said.
Besides the improvement in pain score, the stiffness score was also reduced in the treatment group as compared to the placebo group.
For instance, the stiffness score dropped from 5.38 ± 1.02 to 2.91 ± 1.51 for the treatment group.
For the placebo group, the score, however, increased from 5.17 ± 1.61 to 5.44 ± 1.62.
Source: Journal of Pain Research
Effect Of E-OA-07 On Improving Joint Health and Mobility In Individuals With Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group
Authors: Shalini Srivastava, et al